Biomedical Engineering Reference
In-Depth Information
mN
3500
3000
2500
2000
1500
1000
500
0
*
**
**
0
1
2
3
4
6
8
12
Time (weeks)
Figure 14.9
Tensile strength of biodegradable scaffold
in vitro
. The biodegradable scaffold
used in this study diminished continuously within 1 month. Data represent the mean
±
standard error of fi ve samples at each time point. *
P
<
0.01, * *
P
<
0.001 vs. week 0.
(a)
mN
3000
††† ‡‡
2500
2000
1500
1000
500
0
††
‡
***
***
Control
1M
3M
6M
12M
(b)
mN/mm
6000
*
*
4000
2000
0
Control
1M
3M
6M
12M
Figure 14.10
Increase in mechanical
properties of TEVAs. (a and b) Tensile
strength and stiffness of TEVAs.
P
<
0.001.
* * *
P
<
0.001 vs. inferior vena cava,
† †
P
<
0.01
vs. TEVAs at 1 month,
† † †
P
<
0.001 vs. TEVAs
at 1 month,
‡
P
<
0.05 vs. TEVAs at 3 months,
‡ ‡
P
<
0.01 vs. TEVAs at 3 months.
(b) Stiffness/width was calculated as stiffness
(mN/mm)
=
elastic modulus
(mN/mm
2
)
×
wall thickness (mm).
P
<
0.01.
*
P
<
00.05 vs. TEVAs at 1 month. Data from
dog inferior vena cava are shown as control.
Data represent mean
±
standard error.
size in the TCPC group. There was no evidence of aneurysm formation or calci-
fi cation on cineangiography or computed tomography. All tube grafts were patent
and the diameter of the tube graft increased with time (110
7% of the implanted
size), suggesting that these vascular structure may have the potential for growth,
repair, and remodeling, and provide an important alternative to the use of pros-
thetic materials in the fi eld of pediatric cardiovascular surgery.
±
